<DOC>
	<DOCNO>NCT02080689</DOCNO>
	<brief_summary>The influence Decipher test urologist patient treatment plan choices immediately post RP time PSA rise BCR</brief_summary>
	<brief_title>Prospective Clinical Utility Study Assess Impact Decipher Treatment Decisions After Surgery</brief_title>
	<detailed_description>This prospectively decision impact study evaluate physician patient treatment plan choices review Decipher result eligible patient case . The clinical utility Decipher evaluate patient meet inclusion criterion two time-points post-RP : 1 . In adjuvant setting : within 12 month surgery ( absence detectable PSA rise BCR ) 2 . In salvage setting : post-RP evidence PSA rise BCR ( define PSA detectable rise 2 subsequent determination ) A total 150 patient case , arm , prospectively select clinical site . The study whole enroll 300 patient case . As condition participation study , clinical site must agree provide minimum 10 patient case .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Pathological T3 stage disease ( i.e. , EPE SVI ) , 2 . Positive surgical margin , 3 . Detectable PSA , define PSA detectable rise 2 subsequent determination 1 . For adjuvant setting patient : Metastatic Disease ( M+ ) prior surgery 2 . For salvage set patient : Metastatic Disease PSA rise 3 . Failure PSA nadir surgery 4 . Received neoadjuvant prostate cancer treatment radical prostatectomy 5 . Received adjuvant chemotherapy 6 . Required patient clinical data available evaluation eligibility criterion 7 . For adjuvant setting patient , treatment receive surgery 8 . For salvage setting patient , lack document treatment management recommendation file 9 . Tissue specimen inadequate sample analysis</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>